CA3186844A1 - Use of dexpramipexole for the treatment of moderate to severe asthma - Google Patents

Use of dexpramipexole for the treatment of moderate to severe asthma

Info

Publication number
CA3186844A1
CA3186844A1 CA3186844A CA3186844A CA3186844A1 CA 3186844 A1 CA3186844 A1 CA 3186844A1 CA 3186844 A CA3186844 A CA 3186844A CA 3186844 A CA3186844 A CA 3186844A CA 3186844 A1 CA3186844 A1 CA 3186844A1
Authority
CA
Canada
Prior art keywords
asthma
dexpramipexole
subject
treating
moderate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186844A
Other languages
English (en)
French (fr)
Inventor
Calman Philip PRUSSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Areteia Therapeutics Inc
Original Assignee
Areteia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Areteia Therapeutics Inc filed Critical Areteia Therapeutics Inc
Publication of CA3186844A1 publication Critical patent/CA3186844A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3186844A 2020-08-05 2021-08-05 Use of dexpramipexole for the treatment of moderate to severe asthma Pending CA3186844A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063061226P 2020-08-05 2020-08-05
US63/061,226 2020-08-05
US202163136933P 2021-01-13 2021-01-13
US63/136,933 2021-01-13
US202163147024P 2021-02-08 2021-02-08
US63/147,024 2021-02-08
US202163174938P 2021-04-14 2021-04-14
US63/174,938 2021-04-14
PCT/US2021/044719 WO2022031956A1 (en) 2020-08-05 2021-08-05 Use of dexpramipexole for the treatment of moderate to severe asthma

Publications (1)

Publication Number Publication Date
CA3186844A1 true CA3186844A1 (en) 2022-02-10

Family

ID=80115688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186844A Pending CA3186844A1 (en) 2020-08-05 2021-08-05 Use of dexpramipexole for the treatment of moderate to severe asthma

Country Status (11)

Country Link
US (4) US20220040154A1 (https=)
EP (1) EP4192453A4 (https=)
JP (1) JP2023538278A (https=)
KR (1) KR20230067604A (https=)
CN (1) CN116419746A (https=)
AU (1) AU2021322255A1 (https=)
CA (1) CA3186844A1 (https=)
CL (1) CL2023000296A1 (https=)
IL (1) IL300357A (https=)
MX (1) MX2023001140A (https=)
WO (1) WO2022031956A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260119B (zh) * 2022-07-26 2023-02-10 山东京卫制药有限公司 一种普拉克索昔萘酸盐及其药物缓释制剂
KR20250001767A (ko) 2023-06-29 2025-01-07 재단법인 아산사회복지재단 천식의 분류를 위한 바이오마커 및 이의 용도
WO2025137498A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Matrix tablets of dexpramipexole and methods of manufacturing and use thereof
US20250205206A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
WO2025240942A1 (en) * 2024-05-17 2025-11-20 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of eosinophilic copd

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1730129B1 (en) * 2004-03-19 2011-01-19 Dipharma Francis S.r.l. Intermediates for the preparation of pramipexole
WO2009120927A2 (en) * 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
WO2013034173A1 (en) * 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
EP3838271B1 (en) * 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) * 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2017197360A1 (en) * 2016-05-13 2017-11-16 The Regents Of The University Of California Airway mucus impaction

Also Published As

Publication number Publication date
EP4192453A4 (en) 2024-11-13
US20220040154A1 (en) 2022-02-10
MX2023001140A (es) 2023-05-18
US20240041841A1 (en) 2024-02-08
EP4192453A1 (en) 2023-06-14
AU2021322255A1 (en) 2023-02-23
CL2023000296A1 (es) 2023-08-25
US20260021077A1 (en) 2026-01-22
AU2021322255A8 (en) 2023-03-30
US20240041840A1 (en) 2024-02-08
IL300357A (en) 2023-04-01
KR20230067604A (ko) 2023-05-16
WO2022031956A1 (en) 2022-02-10
CN116419746A (zh) 2023-07-11
JP2023538278A (ja) 2023-09-07

Similar Documents

Publication Publication Date Title
US20260021077A1 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
US20220372066A1 (en) Human squalamine derivatives (ent-06), related compositions comprising the same, and method of using the same
RU2706729C2 (ru) Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба
LaForce et al. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study
JP2024540142A (ja) 慢性副鼻腔炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
HK40090654A (zh) 右旋普拉克索用於治疗中度至重度哮喘的用途
US20250205206A1 (en) Use of dexpramipexole for the treatment of inadequately controlled moderate to severe asthma
CN110831590A (zh) 含有培马贝特的医药
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
Sun et al. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
CN116036090B (zh) 咖啡因及其代谢物在制备治疗口干症的药物中的应用
Borgaonkar et al. Mucus Plugs and Exacerbations in Tobacco-exposed People with Normal and Impaired Spirometry
US20210380706A1 (en) Methods for treating severe asthma in patients with nasal polyposis
Nakaki Drugs that affect autonomic functions or the extrapyramidal system
Zou et al. Specific IgE response to fungi and asthma severity
HK1240824B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
Katano et al. A42 NEW DEVELOPMENTS IN ILD RESEARCH: Six Patients Of Long-Term Survivor With Treatment Of Pirfenidone For Idiopathic Pulmonary Fibrosis
Kuo Small Airways Dysfunction
Hoshino et al. Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting 2-agonist in for patients with asthma
HK1241390B (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
HK1241390A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
CN105326839A (zh) 一种包含盐酸氨溴索的药物组合物及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241122

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250319

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250516

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250801

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260217